Pfizer’s manufacturing arm at risk from Trump tariffs in Europe, Bourla says

Anna Brown

News Reporter

Pfizer CEO Albert Bourla said its manufacturing business could be vulnerable to President Donald Trump’s tariffs in Europe as the pharma giant has “significant” presence …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pfizer’s manufacturing arm at risk from Trump tariffs in Europe, Bourla says

Anna Brown

News Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Roche no longer wants to be where ‘DNA sequencing goes to die’

Trump’s HHS defends drug price negotiations in Novartis suit

First meeting of CDC vaccine advisors in the Kennedy era is postponed

Trump’s picks for NIH, CMS say they’ll unload industry investments

How Keymed steered the China-to-US NewCo model in biotech

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Pfiz­er’s man­u­fac­tur­ing arm at risk from Trump tar­iffs in Eu­rope, Bourla says

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Pfizer’s manufacturing arm at risk from Trump tariffs in Europe, Bourla says